Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2020

View Archived Issues

Drugging resistant androgen receptors

BioVaxys and Ohio State University collaborate to study SARS-CoV-2 vaccine candidate BVX-0320

Congenital hydrocephalus has significant genetic component

[18F]3-F-4-AP shows promise as PET tracer for imaging K+ channels in demyelination in primate models

Xintela's XSTEM shows therapeutic effect in preclinical pig model of ARDS

Positive topline data from phase I/IIa study of IVMED-80 eyedrops

Positive data presented from phase III GEMINI 1 and 2 studies of AGN-190584

First patient dosed in phase II study of BBP-589

Hepagene Therapeutics patents IAP inhibitors

Aligos Therapeutics presents new PRMT5 inhibitors

Merck & Co. synthesizes new compounds for HIV infection

CDK2/cyclin E inhibitors synthesized by Incyte

DermBiont patents compounds for infections and skin disorders

Australian regulatory authorities approve phase I study of APL-1501

Recruitment completed in phase III FORTRESS study of balixafortide

AUR-102: a potent and selective CDK7 inhibitor for cancer treatment

DS-7300a shows potent antitumor effects in B7-H3-expressing cancer models

NMBS-2: a selective and potent HPK1 inhibitor for enhancing antitumor immunity

Scandion Oncology initiates phase Ib pancreatic cancer study of SCO-101

Boehringer Ingelheim initiates phase II study of BI-764198 in patients with COVID-19

New tool probes neurodevelopmental disorder genes

Positive prospective results presented from COVID-19 outpatient trial of REGN-COV2

Aerie initiates phase IIb COMET-1 trial of AR-15512 ophthalmic solution

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...